@entity7704 -test in XXXX : comparison with other dynamic tests.

@entity1 @entity7704 @entity2012 @entity6192 @entity413
@entity1 pancreatic @entity7704 (hpGRF1-44) was given intravenously as a 100 micrograms bolus to 20 @entity1 with active @entity2012 . The GH-responses were variable, ranging from an increase of 8 to 2813% from the basal level (mean +/- SE, 428 +/- 136%). Sixteen GRF-responders (delta% greater than or equal to 100%) were arbitrarily distinguished from four GRF non-responders, whose GH-levels increased less than 100% from basal level after GRF-administration. The outcome of the GRF-test did not correlate with the results of other dynamic tests of GH-secretion in @entity2012 (oral @entity413 tolerance test, insulin hypoglycaemia, TRH-, LHRH-, @entity6192 -stimulation). In 10 @entity1 who had not been treated before, the GH-increments after GRF were higher than those in seven @entity1 who had previously been subjected to transsphenoidal surgery, though they still had clinically and biochemically active @entity2012 . Ten acromegalics, who were tested with GRF, were later treated surgically by the transsphenoidal route and were reevaluated with GRF-stimulation 2 months after surgery. Eight @entity1 appeared clinically cured of whom four had complete normalization and four had significantly lower basal and conventionally stimulated GH-levels postoperatively. These @entity1 also had normal postoperative GH-responses to GRF, which had been significantly higher before surgery compared with normal controls. It is concluded that the GRF-test in @entity2012 does not help in establishing the diagnosis. The normalization of the GH-response to GRF after transsphenoidal surgery seems to represent additional evidence for normalization of GH-secretion, though the latter is not proven by the normal outcome of this test.
